Biofrontera AG (NASDAQ:BFRA) will be discussing 2Q20 financial results with the investment community.on 27th August 2020 at 10:00 AM eastern time.
The company announced the financial results for the quarter on Wednesday 26th August 2020
Those interested in listening to the conference call live via the Internet can visit www.biofrontera.com/en/investors/financial-calendar
Investors who wish to participate in the conference call may call, +49 69201744220 (United States), when prompted, enter passcode 43177738#
Earnings Expectation
Biofrontera AG is reporting second quarter earnings results on Wednesday 26th August 2020, before market open. The consensus estimates from Thomson Reuters are loss of $ 0.16 per share from $ 7.90 million in revenue. For the full year, analysts predict revenues of $ 26.70 million, while looking forward to loss of $ 1.09 per share.
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos over-the-counter line of skin care cosmetics products.
